Clear cell renal cell carcinoma, abbreviated ccRCC, accounts for the majority of kidney cancer diagnoses and is notorious for its resistance to conventional chemotherapy. While targeted therapies and immune checkpoint inhibitors have improved outcomes in recent years, many patients still progress, and the molecular events that drive the disease remain only partially understood. Previous work by the same group had already established that TJP2 is down-regulated in ccRCC tissue, but the biological consequences of that loss, and the mechanism behind them, had stayed in the dark. The new study was designed to close that gap, combining cell-based phenotypic assays, a mouse model of renal tumor growth, and several layers of molecular profiling to trace the chain of cause and effect from TJP2 downward.

The first step was to confirm what TJP2 actually does to cancer cells. When the researchers forced ccRCC cells to over-express the protein, the cells became markedly less capable across the board: proliferation slowed, migration and invasion through matrix-coated surfaces diminished, and apoptosis, the programmed self-destruction that cancer cells usually evade, increased. The opposite held true when TJP2 was depleted. Critically, these effects were not confined to the Petri dish. In a mouse orthotopic model, in which tumor cells are implanted directly into the kidney to mimic the natural tumor environment, TJP2 over-expression significantly restrained tumor growth in vivo. Together, the data positioned TJP2 as a genuine tumor suppressor in this cancer type rather than a passive bystander.

With the phenotype established, the team turned to the harder question: what does TJP2 actually talk to inside the cell? To find out, they performed a proteomic comparison using tandem mass tags, a technique known as TMT profiling that allows many protein samples to be labeled, pooled, and quantified simultaneously in a mass spectrometer. Among the differentially expressed proteins that emerged, one candidate stood out: TIMM21, a subunit of the mitochondrial import inner membrane translocase, a molecular machine that ferries proteins across the inner membrane of mitochondria. The researchers then used co-immunoprecipitation to show that TJP2 physically binds to TIMM21, an interaction that suggested a direct regulatory relationship rather than a distant, indirect one.

The clinical evidence for TIMM21 followed a familiar and sobering pattern. Like TJP2, TIMM21 was found to be under-expressed in ccRCC tissue, and its reduced levels correlated with unfavorable pathological characteristics and poor patient prognosis. In other words, the two proteins decline together, and when they do, patients tend to fare worse. That correlation set up the central mechanistic hypothesis of the paper: TJP2 might suppress kidney cancer by protecting TIMM21 from destruction, and TIMM21 might in turn restrain a growth-promoting signaling cascade that fuels the tumor.

The next experiments tested that hypothesis at the level of protein chemistry. The researchers showed that TJP2 does two things to TIMM21: it promotes the protein’s expression and it inhibits TIMM21’s ubiquitination, the process by which a small tag called ubiquitin marks a protein for disposal by the cell’s proteasome. By shielding TIMM21 from ubiquitin-mediated degradation, TJP2 effectively keeps the mitochondrial translocase subunit at high levels. This kind of post-translational stabilization is a recurring theme in cancer biology, because it allows tumors to eliminate protective factors quickly without ever touching the genes that encode them. Here, the loss of TJP2 removes that protection, letting TIMM21 levels fall and opening the door to unchecked proliferation.

Downstream of TIMM21, the trail led to a signaling pathway familiar to almost every cancer researcher: ERK1/2, the mitogen-activated protein kinase cascade that transmits growth signals from the cell surface to the nucleus. Using a combination of immunoprecipitation, immunofluorescence, Western blotting, quantitative reverse-transcription PCR, and RNA sequencing, the team found that TJP2 over-expression up-regulates SPRY4, a member of the sprouty family of proteins that act as endogenous antagonists of receptor tyrosine kinase signaling, and simultaneously inhibits the phosphorylation of ERK1/2, the activated form of the kinases. In plain terms, the TJP2-TIMM21 axis appears to quiet one of the loudest growth alarms in the cell by boosting a natural silencer of the pathway.

The most convincing evidence came from a series of rescue experiments, the gold standard for establishing causal order in a signaling chain. When the researchers knocked down TIMM21 in cells that had been engineered to over-express TJP2, the growth-inhibiting effects of TJP2 were substantially reversed: the cells resumed proliferating, migrating, and invading, SPRY4 expression dropped, and phosphorylated ERK1/2 climbed back up. Conversely, when SPRY4 was knocked down in cells over-expressing TIMM21, the suppressed cellular phenotypes were similarly rescued and pERK1/2 levels were restored. The symmetry of these results, each manipulation canceling the one above it in the cascade, is what elevates the study from a correlation to a coherent mechanism: TJP2 stabilizes TIMM21, TIMM21 sustains SPRY4, and SPRY4 damps ERK1/2 signaling.

For clinicians, the implications are tantalizing but necessarily preliminary. The TJP2-TIMM21-SPRY4-ERK1/2 axis offers a potential biomarker panel: measuring the levels of these proteins in a tumor sample could, in principle, help stratify patients by risk, since low TIMM21 already correlates with adverse pathology and poor survival in the study’s data. More ambitiously, the pathway suggests therapeutic angles. Drugs that reactivate ERK1/2 restraint, or that prevent the ubiquitination and degradation of TIMM21, could theoretically restore a tumor-suppressive program that ccRCC cells have switched off. The ERK pathway is already heavily drugged in other cancers, with MEK and ERK inhibitors in clinical use, which makes the prospect of repurposing or combining such agents in kidney cancer an obvious next question for translational work.

Caveats remain, as they always do at this stage of research. The mechanistic work rests on engineered cell lines and mouse models, and the human evidence is correlational, drawn from clinical specimens and datasets such as The Cancer Genome Atlas kidney renal clear cell carcinoma cohort. Whether restoring TJP2 or TIMM21 in actual patients is feasible, safe, and effective will require years of additional study. Still, the paper adds a genuinely new branch to the map of kidney cancer biology, connecting a junctional scaffolding protein to mitochondrial protein import and then to one of the most consequential growth pathways in the cell. It is a reminder that tumor suppressors rarely work alone, and that some of the most important players in cancer may be hiding in plain sight among the proteins we thought we already understood. The study was funded by the National Natural Science Foundation of China and conducted with ethical approval and informed consent under the Declaration of Helsinki.

Subject of Research: The TJP2-TIMM21-SPRY4-ERK1/2 signaling axis in clear cell renal cell carcinoma progression

Article Title: TJP2 inhibits clear cell renal cell carcinoma progression by up-regulating TIMM21 to modulate the SPRY4-ERK1/2 signaling pathway

Article References: Jing, T., Wang, C., Xia, M., Xue, L., Tang, T., Peng, D., & Yang, W. (2026). TJP2 inhibits clear cell renal cell carcinoma progression by up-regulating TIMM21 to modulate the SPRY4-ERK1/2 signaling pathway. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08920-6

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08920-6

Keywords: TJP2, TIMM21, SPRY4, ERK1/2, clear cell renal cell carcinoma, tumor suppressor, ubiquitination, proteomics, kidney cancer, MAPK signaling, Journal of Translational Medicine, apoptosis